Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) [Phase 3]

View source ↗

Summary

A Phase 3 study (UNITI-1) evaluated ustekinumab in Crohn's disease patients who failed or were intolerant to TNF antagonists. The trial results were posted in D…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Crohn's Disease, IBD | Phase 3 | Status: COMPLETED | Results posted: 2016-12-07